Published: May 24, 2021
SINGAPORE, May 23, 2021 /PRNewswire/
Genesis MedTech Group ( Genesis ), a leading medical device company, today announced it has completed its Series B round, raising significant growth financing. General Atlantic, a leading global growth equity firm, led the funding with participation from CITIC Capital and others. The majority of shareholders from Series A followed up with additional investments. Lefei Sun, Managing Director and Head of Healthcare for China at General Atlantic, will join the Genesis Board of Directors.
The funds will be used to drive the research and development of new products and the commercialization of existing products, as well as enable business expansion in emerging markets around the world. This acceleration in Genesis model is expected to enable patients and healthcare practitioners in emerging markets to access innovative medtech products that can address unmet needs faced day-to-day-Genesis mission since its inception
Genesis MedTech Group Raises Significant Growth Investment in Latest Round of Series B Financing
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Genesis MedTech Group Raises Significant Growth Investment in Latest Round of Series B Financing
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Genesis Medtech Collaborates with Penumbra to Expand Neurovascular Market in China
- Partnership to be in tandem with formation of Genesis Medtech s Neurovascular Franchise, pending an ongoing full acquisition of Hua Medtech
- The collaboration will position Genesis MedTech ( Genesis ) as the largest local company in China s neurovascular space
News provided by
Share this article
Share this article
SINGAPORE, Jan. 19, 2021 /PRNewswire/ Genesis MedTech Group has reached a consensus to fully acquire Hua Medtech as part of its plans to set up a specialised neurovascular franchise, which has entered into a strategic cooperation with Penumbra, Inc., an NYSE listed, global healthcare company focused on innovative therapies, for the domestic sales and production of products with Penumbra s technology for the Chinese market.